Early Phase 1 Breast Cancer Trial, Not Yet Recruiting NCT07446686 Sponsor: Guizhou Provincial People's Hospital Condition: Breast Cancer
Back to Breast Cancer

Early Phase 1 Breast Cancer Trial, Not Yet Recruiting

NCT07446686
Not Yet Recruiting Early Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are female and between 18 and 75 years old.
  • People whose post-surgery tissue testing confirmed a type of breast cancer that is hormone receptor-positive (HR+) and HER2-negative, meaning the cancer responds to hormones but not to the HER2 protein — defined as at least 10% of cancer cells testing positive for estrogen or progesterone receptors, and HER2 showing as 0 or 1+ on standard testing, or negative on a gene-based test.
  • People for whom no more than 6 months have passed between their breast surgery (full removal or breast-conserving surgery) and entering the trial.
  • People whose post-surgery tissue testing found that cancer had spread to lymph nodes under the arm on the same side as the breast affected (certain other nearby lymph nodes are also considered, with specific counting rules that the trial site can clarify).
  • People whose lymph node results meet specific criteria: either 4 or more lymph nodes contained cancer, or 1 to 3 lymph nodes contained cancer along with at least one additional high-risk factor — such as a primary tumour measuring 5cm or larger, a grade III tumour (not grade II-III), remaining invasive cancer after pre-surgery treatment, or a Ki-67 score of 30% or higher (a measure of how fast the cancer cells are growing).
  • People with an ECOG performance score of 0 to 2, meaning they are able to carry out everyday activities with little to moderate limitation (confirm with trial site).
  • People who have given their written consent and are willing and able to attend scheduled visits, follow the study treatment plan, and complete required tests and procedures.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose tissue testing shows HER2-positive breast cancer, defined as a score of 3+ on standard immunohistochemistry testing or a positive result on a gene-based test.
  • People who have had a local or regional return of breast cancer.
  • People whose cancer is classified as stage IV, meaning it has spread to other parts of the body.
  • People who have cancer in both breasts, including non-invasive cancer (carcinoma in situ) in the opposite breast.
  • People who have a history of serious lung conditions such as interstitial pneumonia.
  • People who have previously received treatment with a CDK4/6 inhibitor, or other anti-cancer biological therapies, targeted therapies, or cancer immunotherapy.
  • People who have had major surgery, taken an experimental drug, or received other anti-cancer treatments or immune-modifying medicines within the 4 weeks before entering the trial (standard surgery, chemotherapy, radiotherapy, and hormone therapy are exceptions — confirm with trial site).
  • People who have other serious physical or mental health conditions, or significant abnormal test results, that in the opinion of the treating doctor could increase risk or affect the reliability of the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 86-13628566285

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Early Phase 1
Sponsor
Guizhou Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
30 April 2027

Primary endpoints

tolerability and safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov